127 related articles for article (PubMed ID: 25499759)
1. Loss of PRDM11 promotes MYC-driven lymphomagenesis.
Fog CK; Asmar F; Côme C; Jensen KT; Johansen JV; Kheir TB; Jacobsen L; Friis C; Louw A; Rosgaard L; Øbro NF; Marquart HV; Anthonsen K; Braat AK; van Lohuizen M; Ralfkiaer E; Grønbæk K; Lund AH
Blood; 2015 Feb; 125(8):1272-81. PubMed ID: 25499759
[TBL] [Abstract][Full Text] [Related]
2. Activating and sustaining c-Myc by depletion of miR-144/451 gene locus contributes to B-lymphomagenesis.
Ding L; Zhang Y; Han L; Fu L; Mei X; Wang J; Itkow J; Elabid AEI; Pang L; Yu D
Oncogene; 2018 Mar; 37(10):1293-1307. PubMed ID: 29284789
[TBL] [Abstract][Full Text] [Related]
3. Myc suppression of Nfkb2 accelerates lymphomagenesis.
Keller U; Huber J; Nilsson JA; Fallahi M; Hall MA; Peschel C; Cleveland JL
BMC Cancer; 2010 Jul; 10():348. PubMed ID: 20598117
[TBL] [Abstract][Full Text] [Related]
4. E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis.
Wolyniec K; Shortt J; de Stanchina E; Levav-Cohen Y; Alsheich-Bartok O; Louria-Hayon I; Corneille V; Kumar B; Woods SJ; Opat S; Johnstone RW; Scott CL; Segal D; Pandolfi PP; Fox S; Strasser A; Jiang YH; Lowe SW; Haupt S; Haupt Y
Blood; 2012 Jul; 120(4):822-32. PubMed ID: 22689861
[TBL] [Abstract][Full Text] [Related]
5. Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation.
Scott CL; Schuler M; Marsden VS; Egle A; Pellegrini M; Nesic D; Gerondakis S; Nutt SL; Green DR; Strasser A
J Cell Biol; 2004 Jan; 164(1):89-96. PubMed ID: 14709542
[TBL] [Abstract][Full Text] [Related]
6. Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis.
Nguyen HV; Vandenberg CJ; Ng AP; Robati MR; Anstee NS; Rimes J; Hawkins ED; Cory S
Blood; 2020 Mar; 135(13):1019-1031. PubMed ID: 31978211
[TBL] [Abstract][Full Text] [Related]
7. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
9. p53 and p73 in suppression of Myc-driven lymphomagenesis.
Griesmann H; Schlereth K; Krause M; Samans B; Stiewe T
Int J Cancer; 2009 Jan; 124(2):502-6. PubMed ID: 18942718
[TBL] [Abstract][Full Text] [Related]
10. MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis.
Sochalska M; Schuler F; Weiss JG; Prchal-Murphy M; Sexl V; Villunger A
Oncogene; 2017 Apr; 36(15):2066-2073. PubMed ID: 27694901
[TBL] [Abstract][Full Text] [Related]
11. Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model.
Borland G; Kilbey A; Hay J; Gilroy K; Terry A; Mackay N; Bell M; McDonald A; Mills K; Cameron E; Neil JC
Oncotarget; 2016 Apr; 7(17):22973-87. PubMed ID: 27056890
[TBL] [Abstract][Full Text] [Related]
12. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
Berg T; Thoene S; Yap D; Wee T; Schoeler N; Rosten P; Lim E; Bilenky M; Mungall AJ; Oellerich T; Lee S; Lai CK; Umlandt P; Salmi A; Chang H; Yue L; Lai D; Cheng SW; Morin RD; Hirst M; Serve H; Marra MA; Morin GB; Gascoyne RD; Aparicio SA; Humphries RK
Blood; 2014 Jun; 123(25):3914-24. PubMed ID: 24802772
[TBL] [Abstract][Full Text] [Related]
13. Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss.
Baudino TA; Maclean KH; Brennan J; Parganas E; Yang C; Aslanian A; Lees JA; Sherr CJ; Roussel MF; Cleveland JL
Mol Cell; 2003 Apr; 11(4):905-14. PubMed ID: 12718877
[TBL] [Abstract][Full Text] [Related]
14. Deletion of the transcriptional regulator TFAP4 accelerates c-MYC-driven lymphomagenesis.
Potts MA; Mizutani S; Garnham AL; Li Wai Suen CSN; Kueh AJ; Tai L; Pal M; Strasser A; Herold MJ
Cell Death Differ; 2023 Jun; 30(6):1447-1456. PubMed ID: 36894688
[TBL] [Abstract][Full Text] [Related]
15. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
Meng X; Carlson NR; Dong J; Zhang Y
Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
[TBL] [Abstract][Full Text] [Related]
17. BCL-W has a fundamental role in B cell survival and lymphomagenesis.
Adams CM; Kim AS; Mitra R; Choi JK; Gong JZ; Eischen CM
J Clin Invest; 2017 Feb; 127(2):635-650. PubMed ID: 28094768
[TBL] [Abstract][Full Text] [Related]
18.
Mathsyaraja H; Freie B; Cheng PF; Babaeva E; Catchpole JT; Janssens D; Henikoff S; Eisenman RN
Genes Dev; 2019 Sep; 33(17-18):1252-1264. PubMed ID: 31395740
[TBL] [Abstract][Full Text] [Related]
19. Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma.
Haery L; Mussakhan S; Waxman DJ; Gilmore TD
Leuk Lymphoma; 2016 Nov; 57(11):2661-71. PubMed ID: 27003102
[TBL] [Abstract][Full Text] [Related]
20. Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency.
Zwolinska AK; Heagle Whiting A; Beekman C; Sedivy JM; Marine JC
Oncogene; 2012 Jul; 31(28):3311-21. PubMed ID: 22081066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
